INDP – indaptus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Indaptus Therapeutics (NASDAQ:INDP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Indaptus Therapeutics (NASDAQ:INDP) was upgraded by analysts at Wall Str
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics GAAP EPS of -$2.98 [Seeking Alpha]
Form 4 Indaptus Therapeutics, For: Dec 23 Filed by: Ben-Tzvi Avraham
Form 4 Indaptus Therapeutics, For: Jan 07 Filed by: NATAN DAVID
Form DEF 14A Indaptus Therapeutics, For: Jan 21
Form 8-K Indaptus Therapeutics, For: Jan 20
Form 3 Indaptus Therapeutics, For: Jan 08 Filed by: NATAN DAVID
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.